A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America (Q46359594)

From Wikidata
Jump to navigation Jump to search
scientific article
edit
Language Label Description Also known as
English
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America
scientific article

    Statements

    A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America (English)

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit